Visualizing hypothesis tests in survival analysis under anticipated delayed effects
What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach...
Saved in:
Published in | Pharmaceutical statistics : the journal of the pharmaceutical industry Vol. 23; no. 6; pp. 870 - 883 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Inc
01.11.2024
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1539-1604 1539-1612 1539-1612 |
DOI | 10.1002/pst.2393 |
Cover
Abstract | What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log‐rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log‐rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log‐rank tests can achieve high power compared to the standard log‐rank test, some choices of weights may lead to type‐I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre‐specified time point τ—a mathematically unambiguous summary measure. However, by emphasizing differences prior to τ, such test statistics may not fully capture the benefit of a new treatment in terms of long‐term survival. In this article, we introduce a graphical approach for direct comparison of weighted log‐rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison. |
---|---|
AbstractList | What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log‐rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log‐rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log‐rank tests can achieve high power compared to the standard log‐rank test, some choices of weights may lead to type‐I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre‐specified time point τ—a mathematically unambiguous summary measure. However, by emphasizing differences prior to τ, such test statistics may not fully capture the benefit of a new treatment in terms of long‐term survival. In this article, we introduce a graphical approach for direct comparison of weighted log‐rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison. What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we anticipate non‐proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log‐rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log‐rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log‐rank tests can achieve high power compared to the standard log‐rank test, some choices of weights may lead to type‐I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre‐specified time point —a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long‐term survival. In this article, we introduce a graphical approach for direct comparison of weighted log‐rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison. What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we anticipate non-proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log-rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log-rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log-rank tests can achieve high power compared to the standard log-rank test, some choices of weights may lead to type-I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre-specified time point τ -a mathematically unambiguous summary measure. However, by emphasizing differences prior to τ , such test statistics may not fully capture the benefit of a new treatment in terms of long-term survival. In this article, we introduce a graphical approach for direct comparison of weighted log-rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison.What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we anticipate non-proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log-rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log-rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log-rank tests can achieve high power compared to the standard log-rank test, some choices of weights may lead to type-I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre-specified time point τ -a mathematically unambiguous summary measure. However, by emphasizing differences prior to τ , such test statistics may not fully capture the benefit of a new treatment in terms of long-term survival. In this article, we introduce a graphical approach for direct comparison of weighted log-rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison. What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we anticipate non-proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log-rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log-rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log-rank tests can achieve high power compared to the standard log-rank test, some choices of weights may lead to type-I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre-specified time point -a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long-term survival. In this article, we introduce a graphical approach for direct comparison of weighted log-rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison. |
Author | Gasperoni, Francesca Magirr, Dominic Jiménez, José L. Barrott, Isobel |
Author_xml | – sequence: 1 givenname: José L. orcidid: 0000-0002-8809-2717 surname: Jiménez fullname: Jiménez, José L. organization: Novartis Pharma A.G – sequence: 2 givenname: Isobel orcidid: 0009-0009-6196-9804 surname: Barrott fullname: Barrott, Isobel organization: Janssen Research & Development L.L.C – sequence: 3 givenname: Francesca orcidid: 0000-0002-1713-9477 surname: Gasperoni fullname: Gasperoni, Francesca organization: Novartis Pharma A.G – sequence: 4 givenname: Dominic orcidid: 0000-0002-3959-7057 surname: Magirr fullname: Magirr, Dominic email: dominic.magirr@novartis.com organization: Novartis Pharma A.G |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38708672$$D View this record in MEDLINE/PubMed |
BookMark | eNp10V1LwzAUBuAgirop-Auk4I03nfls2ksRv2CgsOltSZNTl9G1tWkn9debujlB8Ook5CHnJO8I7ZdVCQidETwhGNOr2rUTyhK2h46JYElIIkL3d2vMj9DIuSXGRMaJOERHLJY4jiQ9RrNX6zpV2E9bvgWLvq7aBTjrghZc6wJbBq5r1natikCVquiHo6400Phta7WtVQsmMFCo3lfIc9CtO0EHuSocnG7rGL3c3c5vHsLp0_3jzfU01IxgFmoqjCJCG5kxk4GhPMqVkoSxjMeADbBMJFJRInAkdUIhF1wTKrLYgOQ8YmN0ubm3bqr3zg-crqzTUBSqhKpzKcOCcMqpGOjFH7qsusa_yCvfUESSS-bV-VZ12QpMWjd2pZo-_fmu3466qZxrIN8RgtMhidQnkQ5JeBpu6IctoP_Xpc-z-bf_AtWMiYc |
Cites_doi | 10.1002/sim.9651 10.1177/17407745211072848 10.1111/sjos.12212 10.1200/JCO.19.03097 10.1080/02664763.2020.1815673 10.1177/1740774520928614 10.1002/sim.9138 10.1200/JCO.19.03111 10.1093/biostatistics/kxt050 10.1002/sim.2864 10.1007/s12561-020-09276-1 10.1002/sim.9444 10.1081/STA-100002138 10.1093/biomet/90.1.15 10.1002/sim.8586 10.32614/CRAN.package.nphRCT 10.1002/pst.1923 10.18637/jss.v070.i08 10.1111/biom.13237 10.1002/sim.9662 10.1001/jamaoncol.2022.2666 10.1002/pst.2267 10.1002/sim.8186 10.1016/j.conctc.2017.09.004 10.1007/s10985-008-9107-z 10.1214/16-AOS1516 10.1016/S0140-6736(16)00587-0 10.1038/s41591-018-0134-3 10.1002/sim.4274 10.1200/JCO.19.01681 10.1200/JCO.20.00015 10.1080/19466315.2019.1697738 10.1002/pst.2091 10.1002/sim.8565 10.1186/s13063-020-4153-2 |
ContentType | Journal Article |
Copyright | 2024 John Wiley & Sons Ltd. 2024 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: 2024 John Wiley & Sons Ltd. – notice: 2024 John Wiley & Sons, Ltd. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
DOI | 10.1002/pst.2393 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1539-1612 |
EndPage | 883 |
ExternalDocumentID | 38708672 10_1002_pst_2393 PST2393 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OC 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 NF~ O66 O9- OIG P2P P2W P2X P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 SUPJJ SV3 UB1 W8V W99 WBKPD WIH WIK WJL WOHZO WQJ WRC WXSBR WYISQ XBAML XG1 XV2 ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 |
ID | FETCH-LOGICAL-c3103-c25da15cd7b3dbed246faa7133b48e0de3b597a215067c92ef54c125b8de74463 |
IEDL.DBID | DR2 |
ISSN | 1539-1604 1539-1612 |
IngestDate | Fri Jul 11 04:03:10 EDT 2025 Fri Jul 25 22:39:47 EDT 2025 Wed Feb 19 02:16:02 EST 2025 Tue Jul 01 02:54:03 EDT 2025 Wed Jan 22 17:14:30 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | score visualization pseudo‐value delayed effects survival test |
Language | English |
License | 2024 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3103-c25da15cd7b3dbed246faa7133b48e0de3b597a215067c92ef54c125b8de74463 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0009-0009-6196-9804 0000-0002-8809-2717 0000-0002-3959-7057 0000-0002-1713-9477 |
PMID | 38708672 |
PQID | 3133567473 |
PQPubID | 1036354 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_3051424256 proquest_journals_3133567473 pubmed_primary_38708672 crossref_primary_10_1002_pst_2393 wiley_primary_10_1002_pst_2393_PST2393 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November/December 2024 2024-11-00 2024 Nov-Dec 20241101 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: November/December 2024 |
PublicationDecade | 2020 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: England – name: Macclesfield |
PublicationTitle | Pharmaceutical statistics : the journal of the pharmaceutical industry |
PublicationTitleAlternate | Pharm Stat |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2017; 8 2021; 20 2011 2009; 80 2019; 37 2017; 45 2020; 17 2020; 39 1998 2020; 38 2019; 38 2016; 387 2011; 30 2019; 18 2022; 41 2020; 12 2016; 70 2020; 76 2022; 49 2018; 24 2023; 42 2021; 15 2003; 90 2023; 22 2023 2022; 8 2016; 43 2014; 15 2019 2020; 21 2021; 40 2001; 30 2009; 15 2007; 26 2022; 19 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 Roychoudhury S (e_1_2_8_11_1) 2021; 15 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_23_1 e_1_2_8_44_1 Hernan MA (e_1_2_8_14_1) 2023 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 Fleming TR (e_1_2_8_21_1) 2011 e_1_2_8_13_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (e_1_2_8_41_1) 2019 Fedorov V (e_1_2_8_36_1) 2009; 80 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 Snapinn S (e_1_2_8_40_1) 2021; 15 The International Council for Harmonisation of technical requirements for Pharmaceuticals for Human use (e_1_2_8_42_1) 1998 e_1_2_8_30_1 |
References_xml | – year: 2011 – volume: 45 start-page: 1988 issue: 5 year: 2017 end-page: 2015 article-title: Asymptotic theory of generalized estimating equations based on jack‐knife pseudo‐observations publication-title: Ann Stat – volume: 41 start-page: 3720 issue: 19 year: 2022 end-page: 3736 article-title: Versatile tests for window mean survival time publication-title: Stat Med – volume: 8 start-page: 1294 year: 2022 end-page: 1300 article-title: Log‐rank test vs maxcombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno‐oncology trials: a systematic review and meta‐analysis publication-title: JAMA Oncol – volume: 38 start-page: 2003 issue: 17 year: 2020 end-page: 2004 article-title: Reply to H. Uno et al and B. Huang et al publication-title: J Clin Oncol – volume: 30 start-page: 2409 issue: 19 year: 2011 end-page: 2421 article-title: The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt publication-title: Stat Med – volume: 90 start-page: 15 issue: 1 year: 2003 end-page: 27 article-title: Generalised linear models for correlated pseudo‐observations, with applications to multi‐state models publication-title: Biometrika – volume: 18 start-page: 287 issue: 3 year: 2019 end-page: 303 article-title: Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects publication-title: Pharm Stat – volume: 70 year: 2016 article-title: Flexsurv: a platform for parametric survival modeling in r publication-title: J Stat Softw – volume: 15 start-page: 241 issue: 2 year: 2009 end-page: 255 article-title: On pseudo‐values for regression analysis in competing risks models publication-title: Lifetime Data Anal – volume: 15 start-page: 1 year: 2021 end-page: 3 article-title: Comment on “Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross‐pharma working group”: the test statistic should estimate some reasonable measure of treatment benefit publication-title: Stat Biopharm Res – volume: 37 start-page: 3455 issue: 35 year: 2019 article-title: Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis? publication-title: J Clin Oncol – volume: 40 start-page: 5521 issue: 25 year: 2021 end-page: 5533 article-title: Window mean survival time publication-title: Stat Med – volume: 38 start-page: 2000 issue: 17 year: 2020 end-page: 2001 article-title: Is the log‐rank and hazard ratio test/estimation the best approach for primary analysis for all trials? publication-title: J Clin Oncol Off J Am Soc Clin Oncol – volume: 17 start-page: 507 issue: 5 year: 2020 end-page: 521 article-title: Comparison of survival distributions in clinical trials: a practical guidance publication-title: Clin Trials – volume: 30 start-page: 591 issue: 4 year: 2001 end-page: 608 article-title: Equivalence between score and weighted tests for survival curves publication-title: Commun Stat Theory Methods – volume: 43 start-page: 845 issue: 3 year: 2016 end-page: 862 article-title: A note on the large sample properties of estimators based on generalized linear models for correlated pseudo‐observations publication-title: Scand J Stat – volume: 15 start-page: 1 year: 2021 end-page: 15 article-title: Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross‐pharma working group publication-title: Stat Biopharm Res – volume: 21 start-page: 1 issue: 1 year: 2020 end-page: 17 article-title: A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time‐to‐event outcome publication-title: Trials – volume: 387 start-page: 1837 issue: 10030 year: 2016 end-page: 1846 article-title: Atezolizumab versus docetaxel for patients with previously treated non‐small‐cell lung cancer (poplar): a multicentre, open‐label, phase 2 randomised controlled trial publication-title: The Lancet – volume: 24 start-page: 1441 issue: 9 year: 2018 end-page: 1448 article-title: Blood‐based tumor mutational burden as a predictor of clinical benefit in non‐small‐cell lung cancer patients treated with atezolizumab publication-title: Nat Med – volume: 19 start-page: 201 issue: 2 year: 2022 end-page: 210 article-title: Design and analysis of group‐sequential clinical trials based on a modestly‐weighted log‐rank test in anticipation of a delayed separation of survival curves: a practical guidance publication-title: Clin Trials – year: 1998 – volume: 80 start-page: 50 issue: 1 year: 2009 end-page: 61 article-title: Consequences of dichotomization publication-title: Pharm Stat J Appl Stat Pharm Ind – volume: 42 start-page: 936 year: 2023 end-page: 952 article-title: Ratio and difference of average hazard with survival weight: new measures to quantify survival benefit of new therapy publication-title: Stat Med – volume: 15 start-page: 222 issue: 2 year: 2014 end-page: 233 article-title: Predicting the restricted mean event time with the subject's baseline covariates in survival analysis publication-title: Biostatistics – volume: 12 start-page: 187 issue: 2 year: 2020 end-page: 198 article-title: Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis publication-title: Stat Biopharm Res – volume: 39 start-page: 2655 issue: 20 year: 2020 end-page: 2670 article-title: On permutation tests for comparing restricted mean survival time with small sample from randomized trials publication-title: Stat Med – year: 2023 – volume: 42 start-page: 1139 year: 2023 end-page: 1155 article-title: On assessing survival benefit of immunotherapy using long‐term restricted mean survival time publication-title: Stat Med – volume: 26 start-page: 4505 issue: 24 year: 2007 end-page: 4519 article-title: Analyzing survival curves at a fixed point in time publication-title: Stat Med – volume: 38 start-page: 2001 issue: 17 year: 2020 end-page: 2002 article-title: Estimating treatment effect as the primary analysis in a comparative study: moving beyond p value publication-title: J Clin Oncol Off J Am Soc Clin Oncol – volume: 38 start-page: 3782 issue: 20 year: 2019 end-page: 3790 article-title: Modestly weighted logrank tests publication-title: Stat Med – volume: 12 start-page: 225 year: 2020 end-page: 245 article-title: On weighted log‐rank combination tests and companion cox model estimators publication-title: Stat Biosci – volume: 8 start-page: 147 year: 2017 end-page: 155 article-title: Estimation of treatment effects in weighted log‐rank tests publication-title: Contem Clin Trials Commun – volume: 76 start-page: 1157 issue: 4 year: 2020 end-page: 1166 article-title: On the empirical choice of the time window for restricted mean survival time publication-title: Biometrics – volume: 39 start-page: 2949 issue: 22 year: 2020 end-page: 2961 article-title: Regression models using parametric pseudo‐observations publication-title: Stat Med – year: 2019 – volume: 49 start-page: 466 issue: 2 year: 2022 end-page: 484 article-title: Quantifying treatment differences in confirmatory trials under non‐proportional hazards publication-title: J Appl Stat – volume: 22 start-page: 181 issue: 1 year: 2023 end-page: 193 article-title: Treatment effect measures under nonproportional hazards publication-title: Pharm Stat – volume: 20 start-page: 512 issue: 3 year: 2021 end-page: 527 article-title: Non‐proportional hazards in immuno‐oncology: is an old perspective needed? publication-title: Pharm Stat – ident: e_1_2_8_33_1 doi: 10.1002/sim.9651 – volume: 80 start-page: 50 issue: 1 year: 2009 ident: e_1_2_8_36_1 article-title: Consequences of dichotomization publication-title: Pharm Stat J Appl Stat Pharm Ind – ident: e_1_2_8_22_1 doi: 10.1177/17407745211072848 – ident: e_1_2_8_37_1 – ident: e_1_2_8_28_1 doi: 10.1111/sjos.12212 – ident: e_1_2_8_5_1 doi: 10.1200/JCO.19.03097 – ident: e_1_2_8_10_1 doi: 10.1080/02664763.2020.1815673 – ident: e_1_2_8_8_1 doi: 10.1177/1740774520928614 – ident: e_1_2_8_31_1 doi: 10.1002/sim.9138 – ident: e_1_2_8_4_1 doi: 10.1200/JCO.19.03111 – ident: e_1_2_8_25_1 doi: 10.1093/biostatistics/kxt050 – ident: e_1_2_8_26_1 doi: 10.1002/sim.2864 – ident: e_1_2_8_15_1 doi: 10.1007/s12561-020-09276-1 – ident: e_1_2_8_39_1 doi: 10.1002/sim.9444 – ident: e_1_2_8_23_1 doi: 10.1081/STA-100002138 – ident: e_1_2_8_18_1 doi: 10.1093/biomet/90.1.15 – ident: e_1_2_8_35_1 doi: 10.1002/sim.8586 – volume: 15 start-page: 1 year: 2021 ident: e_1_2_8_40_1 article-title: Comment on “Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross‐pharma working group”: the test statistic should estimate some reasonable measure of treatment benefit publication-title: Stat Biopharm Res – ident: e_1_2_8_45_1 doi: 10.32614/CRAN.package.nphRCT – ident: e_1_2_8_43_1 – ident: e_1_2_8_9_1 doi: 10.1002/pst.1923 – ident: e_1_2_8_38_1 doi: 10.18637/jss.v070.i08 – volume-title: Causal Inference. Chapman & Hall/CRC Monographs on Statistics & Applied Probab year: 2023 ident: e_1_2_8_14_1 – volume-title: Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials year: 2019 ident: e_1_2_8_41_1 – ident: e_1_2_8_44_1 doi: 10.1111/biom.13237 – volume-title: Counting Processes and Survival Analysis year: 2011 ident: e_1_2_8_21_1 – ident: e_1_2_8_32_1 doi: 10.1002/sim.9662 – volume-title: Statistical Principles for Clinical Trials (e9 year: 1998 ident: e_1_2_8_42_1 – ident: e_1_2_8_12_1 doi: 10.1001/jamaoncol.2022.2666 – ident: e_1_2_8_34_1 doi: 10.1002/pst.2267 – ident: e_1_2_8_17_1 doi: 10.1002/sim.8186 – ident: e_1_2_8_16_1 doi: 10.1016/j.conctc.2017.09.004 – ident: e_1_2_8_27_1 doi: 10.1007/s10985-008-9107-z – ident: e_1_2_8_29_1 doi: 10.1214/16-AOS1516 – ident: e_1_2_8_19_1 doi: 10.1016/S0140-6736(16)00587-0 – ident: e_1_2_8_20_1 doi: 10.1038/s41591-018-0134-3 – ident: e_1_2_8_24_1 doi: 10.1002/sim.4274 – volume: 15 start-page: 1 year: 2021 ident: e_1_2_8_11_1 article-title: Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross‐pharma working group publication-title: Stat Biopharm Res – ident: e_1_2_8_2_1 doi: 10.1200/JCO.19.01681 – ident: e_1_2_8_3_1 doi: 10.1200/JCO.20.00015 – ident: e_1_2_8_6_1 doi: 10.1080/19466315.2019.1697738 – ident: e_1_2_8_13_1 doi: 10.1002/pst.2091 – ident: e_1_2_8_30_1 doi: 10.1002/sim.8565 – ident: e_1_2_8_7_1 doi: 10.1186/s13063-020-4153-2 |
SSID | ssj0017895 |
Score | 2.3388884 |
Snippet | What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time‐to‐event endpoint when we... What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 870 |
SubjectTerms | Data Interpretation, Statistical delayed effects Humans Models, Statistical Proportional Hazards Models pseudo‐value Randomized Controlled Trials as Topic - methods Randomized Controlled Trials as Topic - statistics & numerical data Research Design score Survival Analysis survival test Time Factors visualization |
Title | Visualizing hypothesis tests in survival analysis under anticipated delayed effects |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpst.2393 https://www.ncbi.nlm.nih.gov/pubmed/38708672 https://www.proquest.com/docview/3133567473 https://www.proquest.com/docview/3051424256 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6yJy--H_VFBNnTdrdN09dRfCCCsuiuCB5Kkqa4CN3FtIf11zvTxy4qgngKJSlJM5nJN-nMF0LOPBbpOJCR7cdxhqdV0haRy21wxKSjVMacKkns7j64GfPbZ_-5iarEXJiaH2Jx4IaaUdlrVHAhzWBJGjozRR_5u8D8ul6AtPmXDwvmKDeMqgtXQJ9j2w0c3vLOOmzQvvh1J_oBL7-i1Wq7uV4nL-1A6yiTt35ZyL76-Mbh-L8v2SBrDQql5_Wy2SQrOt8i3WFNYz3v0dEyK8v0aJcOlwTX823y-DQxmIv5AdsefZ3PMInLTAwF1FoYOsmpKcEAwRKmoqE8oZiq9g6PTQy3TimyU86hbAJKdsj4-mp0cWM3lzPYCq8msxXzU-H6Kg2ll0qdMh5kQqDLK3mknVR7EnwVwZDBMFQx05nPFaApGaU6BB_U2yWdfJrrfUKFH7NIpU4ms4xzxgTnMvYyAH6uxD3cIqetoJJZzcGR1GzLLIG5S3DuLHLUSjBptNAkHozGD8BhgurTRTXoD_4UEbmeltAGCeDR7wossldLftGJB8YsCkJmkW4lv197T4aPIywP_trwkKwyQEd1UuMR6RTvpT4GdFPIk2odfwIjd_hL |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB7xOMCFZXl2FxYjoZ5ISRznJU4IFpWnKiiIA1JkO46okEJF0kP59TuTRytAKyFOVmRHdjwezzeO5xuAPZeHJvJVaHlRlNJplbJk6AgLHTFla51yuwwSu7r2u3fi_MF7mIHDJham4oeYHLiRZpT7NSk4HUgfTFlDh3nRIQKvWZgXiDPI8zq5mXBHOUFYplxBjY4sx7dFwzxr84Pmzfe26BPAfI9XS4Nz-gMem6FW90yeO6NCdfTbBxbHb37LMizVQJQdVSvnJ8yYbAXavYrJerzP-tPArHyftVlvynE9XoXb-0FO4ZhvaPnY03hIcVz5IGcIXIucDTKWj3APwlXMZM16wiha7RUf62vcJmFEUDnGsr5TsgZ3p3_7x12rzs9gacpOZmnuJdLxdBIoN1Em4cJPpSSvV4nQ2IlxFborkhOJYaAjblJPaARUKkxMgG6ouw5z2UtmNoFJL-KhTuxUpakQnEshVOSmiP0cRWa8BbuNpOJhRcMRV4TLPMa5i2nuWrDViDCuFTGPXRyN56PPhNW7k2pUIfovIjPzMsI2xAFPrpffgo1K9JNOXNzPQj_gLWiXAvxv73Hvtk_lr6823IGFbv_qMr48u774DYscwVIV47gFc8XryGwj2CnUn3JR_wOhuPxq |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB-sgvTFVq16rdoVyj2ZM9lsvh5L62FbK0c9i-BD2E88hHiY3MP513cmH3fYUhCflrAbdrOzs_ObzcxvAT6FPLVZrFIvyjJHp1XKk2kgPHTElK-1436dJPbzIj67Et-vo-s2qpJyYRp-iMWBG2lGvV-Tgk-NO1mShk7LakD8Xa9gTcQIJAgQ_VpQRwVJWt-4ggqdeUHsi4541ucn3ZtPTdE_-PIpXK3tzfAN3HQjbcJM7gazSg30418kji_7lLew0cJQ9rlZN5uwYost6I8aHuv5MRsv07LKY9ZnoyXD9XwbLn9PSkrGfES7x27nU8riKiclQ9halWxSsHKGOxCuYSZbzhNGuWoP-NgGcVvDiJ5yjmUbUfIOroan4y9nXns7g6fpbjJP88jIINImUaFR1nAROynJ51Uitb6xoUJnRXKiMEx0xq2LhEY4pVJjE3RCwx1YLe4LuwdMRhlPtfGdck4IzqUQKgsdIr9AkRHvwVEnqHzakHDkDd0yz3Hucpq7Hux3EsxbNSzzEEcTxegxYfXRohoViP6KyMLez7ANMcCT4xX3YLeR_KKTEHezNE54D_q1_P7bez66HFP5_rkNP8L66OswP_928eMDvOaIlJoEx31YrR5m9gCRTqUO6yX9B72m-xk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visualizing+hypothesis+tests+in+survival+analysis+under+anticipated+delayed+effects&rft.jtitle=Pharmaceutical+statistics+%3A+the+journal+of+the+pharmaceutical+industry&rft.au=Jim%C3%A9nez%2C+Jos%C3%A9+L&rft.au=Barrott%2C+Isobel&rft.au=Gasperoni%2C+Francesca&rft.au=Magirr%2C+Dominic&rft.date=2024-11-01&rft.issn=1539-1612&rft.eissn=1539-1612&rft.volume=23&rft.issue=6&rft.spage=870&rft_id=info:doi/10.1002%2Fpst.2393&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-1604&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-1604&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-1604&client=summon |